Utilization, cost, and outcome of branded vs compounded 17-alpha hydroxyprogesterone caproate in prevention of preterm birth. Fried*, I., Beam*, A. L, Kohane, I. S, & Palmer, N. P JAMA internal medicine, 177(11):1689–1690, American Medical Association, 2017.
bibtex   
@article{fried2017utilization,
  title={Utilization, cost, and outcome of branded vs compounded 17-alpha hydroxyprogesterone caproate in prevention of preterm birth},
  author={Fried*, Inbar and Beam*, Andrew L and Kohane, Isaac S and Palmer, Nathan P},
  journal={JAMA internal medicine},
  volume={177},
  number={11},
  pages={1689--1690},
  year={2017},
  keywords={Healthcare},
  publisher={American Medical Association}
}

Downloads: 0